Buhle Moyo

Accomplished scientist with expertise in biochemistry, CRISPR gene editing, and AAV capsid engineering. Proven track record of leading multi-institutional projects, securing funding, and publishing research in prestigious journals. Skilled in mentoring research staff, facilitating interdisciplinary collaborations, and presenting findings at national and international conferences. Proficient in adapting to dynamic research requirements and achieving impactful outcomes.

Selected Publications & Research Highlights

• Moyo, B., Brown, L. B., Khondaker, I. I., & Bao, G. (2025). Engineering adeno-associated viral vectors for CRISPR/Cas-based in vivo therapeutic genome editing. Biomaterials, 123314.
• Greenwood, E., Cao, M., Lee, C. M., Liu, A., Moyo, B., Bao, G., & Gibson, G. (2025). Haplotype rather than single causal variant effects contribute to regulatory gene expression associations in human myeloid cells. bioRxiv, 2025-.
• Collins, L. T., Beatty, W., Moyo, B., Alves-Bezerra, M., Hurley, A., Lou, Q., … & Curiel, D. T. (2023). Encapsulation of AAVs into protein vault nanoparticles as a solution to neutralizing antibody challenges in gene therapy. bioRxiv, 2023-11.
• Collins, L. T., Beatty, W., Boucher, P., Moyo, B., Alves-Bezerra, M., Hurley, A., … & Lu, Z. H. (2024). Covalently linked adenovirus-AAV complexes as a novel platform for gene therapy delivery. bioRxiv, 2024-.
• Thadani, N. N., Yang, J., Moyo, B., Lee, C. M., Chen, M. Y., Bao, G., & Suh, J. (2020). Site-specific post-translational surface modification of adeno-associated virus vectors using leucine zippers. ACS Synthetic Biology, 9(3), 461–467.
• Tong, S., Moyo, B., Lee, C. M., Leong, K., & Bao, G. (2019). Engineered materials for in vivo delivery of genome-editing machinery. Nature Reviews Materials, 4(11), 726–737. (Co-first author)
• Scott, T., Moyo, B., Nicholson, S., Maepa, M. B., Watashi, K., Ely, A., … & Arbuthnot, P. (2017). ssAAVs encoding SaCas9 and guides targeting hepatitis B virus inhibit viral replication in cultured cells. Scientific Reports, 7(1), 7401.
• Moyo, B., Bloom, K., Scott, T., Ely, A., & Arbuthnot, P. (2018). CRISPR/Cas-mediated gene editing approaches for treating hepatitis B and C virus infections. Virus Research, 244, 311–320.
• Moyo, B., Nicholson, S. A., & Arbuthnot, P. B. (2016). Long non-coding RNAs in hepatitis B virus-related hepatocellular carcinoma. Virus Research, 212, 103–113.

Highlights:

• Led projects advancing AAV and CRISPR-based in vivo delivery platforms for therapeutic applications.
• Contributed to translational research in gene therapy for viral infections and genetic disorders.
• Co-first author on high-impact review articles bridging materials engineering with genome editing delivery strategies.

• Directed Multi-Institutional Projects: Led a $2M AAV delivery program, coordinating cross-institutional teams to achieve research milestones and accelerate translational outcomes.
• Published Research: Authored 15+ peer-reviewed publications in high-impact journals, advancing gene therapy, AAV vector engineering, and genome editing technologies.
• Secured Research Funding: Successfully obtained grants to support innovative in vivo gene editing and therapeutic development projects.
• Team Leadership & Mentoring: Trained and supervised 20+ research staff and students, fostering technical skill development, collaboration, and high-performing team culture.